A team of researchers led by Dr. Kim V. Narry, director of the Center for RNA Research at the Institute for Basic Science ...

Drug developers will now have enhanced abilities to rapidly prototype, test, iterate, and scale up their mRNA therapeutics.

Sunshine Biopharma's K1.1 mRNA-LNP shows promise for HCC treatment in mice, while its 2024 revenue surged 45% to $34.9 ...

Researchers at the University of Cologne and University Hospital Cologne have determined that the novel mRNA-based COVID-19 ...

A new study conducted by researchers at Hokkaido University has unveiled a novel class of zwitterionic phospholipids capable ...

Researchers develop innovative phospholipids that improve the functional delivery of mRNA via lipid nanoparticles, paving the ...

FORT LAUDERDALE, FL / ACCESS Newswire / April 2, 2025 / Sunshine Biopharma Inc. (NASDAQ:SBFM) ("We", "Our", the "Company"), a ...

A study conducted by researchers at Hokkaido University has unveiled a novel class of zwitterionic phospholipids capable of ...

Customers looking for an mRNA therapeutic partner should prioritize operational excellence and choose flexible CDMOs.

Sunshine Biopharma (SBFM) has completed additional studies on orthotopic human tumor models in mice confirming its K1.1 mRNA Lipid ...

The anti-melanogenesis effect of ligustroside derived from Ligustrum japonicum and its underlying mechanisms are explored.